Clinical trial NCT02226354: Study of the Safety and Efficacy of Dietary Buglossoides Oil
Official title: Study of the Safety and Efficacy of Dietary Buglossoides Oil
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: Dietary vegetable oil
Stearidonic acid
Tissue
Fatty Acid
composition
Lead sponsor: Réseau de Santé Vitalité Health Network
Sponsor class: OTHER
First posted: 2014-08-27
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Seeds from the Buglossoides arvensis plant (trademarked as Ahiflower™) produce oil that is a rich natural source (20%) of stearidonic acid (SDA), a metabolic intermediate between omega-3 fatty acids found in other plants (such as flax) and those found in fish oils.

The objectives of this study to collect safety data and to investigate the accumulation of long chain n-3 polyunsaturated fatty acids in human lipids following oral supplementation with Ahiflower oil in healthy adults.

Detailed description: This is a single-center, randomized, comparator-controlled, double-blind study in healthy subjects. Forty subjects will be randomly assigned to 2 supplementation groups (n=20 per group). One group will consume 10 ml of Buglossoides oil daily and one group will consume 10 ml of flax seed oil daily for a 4 week period. Baseline data will be obtained at week 0. Subjects will return to the clinic after 2 weeks and again after 4 weeks for measurement of safety and efficacy endpoints.

The efficacy parameters are statistically significant changes from baseline and between groups in plasma, red blood cell and leukocyte omega-3 fatty acid content.

The primary efficacy endpoint will be:

Plasma EPA concentration expressed as μmol/L plasma.

The secondary efficacy endpoints will be:

1. Plasma 20:4n-3 and DPA individually as μmol/L;
2. Plasma 20:4n-3, EPA and DPA individually as % of total fatty acids;
3. Erythrocyte 20:4n-3, EPA and DPA individually as % of total fatty acids;
4. Mononuclear cell 20:4n-3, EPA and DPA individually as % of total fatty acids;
5. Neutrophil 20:4n-3, EPA and DPA individually as % of total fatty acids;
6. The omega-3 index (defined as the sum of red blood cell EPA and DHA concentrations), expressed as % total fatty acids.

Safety endpoints will be:

1. fasting serum chemistry
2. fasting hematology profile
3. fasting blood lipid profile

Eligibility criteria: Inclusion Criteria:

* Men or non-pregnant women, using an effective form of birth control (such as oral contraceptives, injectable contraceptives or the barrier method such as a intrauterine device (IUD) with a spermicide, a diaphragm with a spermicide, a condom with a spermicide or a sponge with a spermicide) for at least 3 months prior to entry into the study and continuing during participation in the study.
* 18 to 65 years of age, inclusive.
* Body mass index (BMI) 18 - 35 kg/m2
* Subject is willing to avoid alcohol consumption for 24h prior to every clinic visit.
* The subject will not modify smoking habits during supplementation period.
* No significant medical conditions that in the opinion of the qualified physician, would preclude the subject's participation in the study.
* Signed informed consent.
* Willing to follow all study procedures including study visits, fasting blood draws, stable body weight, normal eating habits, current activity level, and compliance with study preparation.
* Willing to not consume fish, crustaceans and shellfish for the duration of the study.

Exclusion Criteria:

* Pregnancy or lactation. Women trying to conceive. Women who will try to conceive who are unwilling to commit to the use of a medically approved form of contraception throughout the study period. Method of contraception must be recorded in the case report file.
* Individual has a condition the study physician believes would interfere with the participant's ability to provide informed consent, comply with his responsibilities during the study, which might confound the interpretation of the study results or put the person at undue risk.
* Medical conditions including an active peptic ulcer, inflammatory bowel disease, or gastrointestinal bleeding and any medical condition or prior gastrointestinal surgery that could influence absorption, metabolism or excretion of the study supplement.
* History or presence of significant, renal, hepatic, gastrointestinal, pulmonary, biliary, neurological or endocrine disorders.
* History or presence of cancer in the past 2 yrs, except for non-melanoma skin cancers (e.g. basal or squamous cell carcinoma of the skin).
* Clinically significant abnormal laboratory test results including but not limited to LDL-cholesterol ≥ 4.1mM, triglyceride levels ≥3.95mM, fasting creatinine ≥ 1.5 mg/dL, alkaline phosphatase or aspartate aminotransferase ≥ 1.5 times the upper limit of normal.
* Currently being treated for angina, arrhythmia and/or congestive heart failure. History of myocardial infarction or stroke.
* Presence of coronary heart disease or presence of multiple risk factors that result in a greater than 20% chance for developing coronary artery disease within 10 years using the Framingham risk index.
* Uncontrolled hypertension (resting systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg).
* Type 1 or 2 diabetes. Fasting glucose ≥ 100 mg/dL. HbA1c ≥ 6.0.
* If a smoker, subject smokes no more than 1 pack (20 cigarettes) daily.
* History (within 12 months) or current alcohol or substance abuse (no more than 14 consumptions per week; 1 consumption= 12 oz beer, 5 oz wine, 1.5 oz distilled spirits).
* Use of any lipid-altering medications (statins, bile acid sequestrants, cholesterol absorption inhibitors, fibrates, prescription formulations of niacin).
* Unstable use of thyroid medication. Stable, treated hypothyroidism is not an exclusion criteria.
* Use of any weight loss or lipid metabolism medication/supplement/program (including lipase inhibitors) within 1 month of study period OR weight gain or loss \> 2 kg in the past 3 months.
* Currently taking fish oil or any other omega-3 or omega-6 polyunsaturated fatty acid supplement/drug within three months of Visit 1 and throughout the study. Consumption of fatty fish (salmon, herring, mackerel, albacore tuna, and sardines) more than twice a month within three months of visit 1 and throughout the study period. Consumption (more than twice a month) of any EPA/DHA enriched foods (e.g. DHA-enriched eggs) within three months of Visit 1. Unwillingness to avoid all fish including shellfish and crustaceans throughout the study period.
* Use of alpha-linolenic acid-containing seeds and oils such as flax seed, perilla seed, hemp, spirulina, walnut, mustard seed or black currant seeds/oil within three months of Visit 1 and throughout the study.
* Use of an investigational product within the previous 30 days.
* Has donated blood up to 8 weeks before the start of the study. Not willing to cease being a blood donor during the study.

Primary outcomes:
measure: Plasma eicosapentaenoic acid (EPA) concentration
timeFrame: Day 0, Day 14, Day 28
Secondary outcomes:
measure: Plasma eicosatetraenoic acid (ETA) concentration
timeFrame: Day 0, Day 14, Day 28
measure: Plasma docosapentaenoic acid (DPA) concentration
timeFrame: Day 0, Day 14, Day 28
measure: Plasma 20:4n-3, EPA and DPA individually as % of total fatty acids
timeFrame: Day 0, Day 14, Day 28
measure: Erythrocyte 20:4n-3, EPA and DPA individually as % of total fatty acids
timeFrame: Day 0, Day 14, Day 28
measure: Mononuclear cell 20:4n-3, EPA and DPA individually as % of total fatty acids
timeFrame: Day 0, Day 14, Day 28
measure: Neutrophil 20:4n-3, EPA and DPA individually as % of total fatty acids
timeFrame: Day 0, Day 14, Day 28
measure: Omega-3 index (defined as the sum of red blood cell EPA and DHA concentrations)
timeFrame: Day 0, Day 14, Day 28
measure: Fasting serum chemistry: glucose
timeFrame: Day 0, Day 14, Day 28
measure: Fasting serum chemistry: calcium
timeFrame: Day 0, Day 14, Day 28
measure: Fasting serum chemistry: sodium
timeFrame: Day 0, Day 14, Day 28
measure: Fasting serum chemistry: potassium
timeFrame: Day 0, Day 14, Day 28
measure: Fasting serum chemistry: blood urea nitrogen
timeFrame: Day 0, Day 14, Day 28
measure: Fasting serum chemistry: creatinine
timeFrame: Day 0, Day 14, Day 28
measure: Fasting serum chemistry: alkaline phosphatase
timeFrame: Day 0, Day 14, Day 28
measure: Fasting serum chemistry: aspartate aminotransferase
timeFrame: Day 0, Day 14, Day 28
measure: Fasting serum chemistry: gamma-glutamyl transferase
timeFrame: Day 0, Day 14, Day 28
measure: Fasting serum chemistry: total bilirubin
timeFrame: Day 0, Day 14, Day 28
measure: Fasting serum chemistry: amylase
timeFrame: Day 0, Day 14, Day 28
measure: Fasting serum chemistry: uric acid
timeFrame: Day 0, Day 14, Day 28
measure: Fasting serum chemistry: albumin
timeFrame: Day 0, Day 14, Day 28
measure: Fasting hematology profile: white blood cell count
timeFrame: Day 0, Day 14, Day 28
measure: Fasting hematology profile: neutrophil count
timeFrame: Day 0, Day 14, Day 28
measure: Fasting hematology profile: red blood cell count
timeFrame: Day 0, Day 14, Day 28
measure: Fasting hematology profile: hemoglobin
timeFrame: Day 0, Day 14, Day 28
measure: Fasting hematology profile: hematocrit
timeFrame: Day 0, Day 14, Day 28
measure: Fasting hematology profile: platelet count
timeFrame: Day 0, Day 14, Day 28
measure: Fasting blood lipid profile: triglycerides
timeFrame: Day 0, Day 14, Day 28
measure: Fasting blood lipid profile: total cholesterol
timeFrame: Day 0, Day 14, Day 28
measure: Fasting blood lipid profile: LDL-C
timeFrame: Day 0, Day 14, Day 28
measure: Fasting blood lipid profile: non HDL-C
timeFrame: Day 0, Day 14, Day 28
measure: Fasting blood lipid profile: HDL-C
timeFrame: Day 0, Day 14, Day 28
measure: Fasting serum chemistry: chlorides
timeFrame: Day 0, Day 14, Day 28
measure: Estimated glomerular filtration rate
timeFrame: Day 0, Day 14, Day 28
measure: Fasting serum chemistry: direct bilirubin
timeFrame: Day 0, Day 14, Day 28
measure: Fasting hematology profile: mean corpuscular volume
timeFrame: Day 0, Day 14, Day 28
measure: Fasting hematology profile: mean corpuscular hemoglobin
timeFrame: Day 0, Day 14, Day 28
measure: Fasting hematology profile: mean corpuscular hemoglobin concentration
timeFrame: Day 0, Day 14, Day 28
measure: Fasting hematology profile: red cell distribution width
timeFrame: Day 0, Day 14, Day 28
measure: Fasting hematology profile: mean platelet volume
timeFrame: Day 0, Day 14, Day 28
measure: Fasting hematology profile: lymphocyte concentration
timeFrame: Day 0, Day 14, Day 28
measure: Fasting hematology profile: monocyte count
timeFrame: Day 0, Day 14, Day 28
measure: Fasting hematology profile: eosinophil count
timeFrame: Day 0, Day 14, Day 28
measure: Fasting hematology profile: basophil count
timeFrame: Day 0, Day 14, Day 28
measure: Fasting hematology profile: immature granulocytes count
timeFrame: Day 0, Day 14, Day 28
measure: Fasting hematology profile: immature granulocytes (% of WBC)
timeFrame: Day 0, Day 14, Day 28
measure: Fasting hematology profile: neutrophil (% of WBC)
timeFrame: Day 0, Day 14, Day 28
measure: Fasting hematology profile: lymphocyte (% of WBC)
timeFrame: Day 0, Day 14, Day 28
measure: Fasting hematology profile: monocyte (% of WBC)
timeFrame: Day 0, Day 14, Day 28
measure: Fasting hematology profile: eosinophil (% of WBC)
timeFrame: Day 0, Day 14, Day 28
measure: Fasting hematology profile: basophil (% of WBC)
timeFrame: Day 0, Day 14, Day 28
Other outcomes:
Locations:
city: Moncton
country: Canada
facility: Université de Moncton
state: New Brunswick
Study officials:
affiliation: Université de Moncton
name: Marc Surette, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Centre Hospitalier Dr Georges-L.-Dumont
name: Rémi LeBlanc, MD
role: PRINCIPAL_INVESTIGATOR
References: